National Vaccine Injury Compensation Program; List of Petitions Received, 38103-38105 [2021-15223]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
lotter on DSK11XQN23PROD with NOTICES1
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2007–D–0369 for ‘‘Draft Guidance for
Cilastatin Sodium; Imipenem;
Relebactam.’’ Received comments will
be placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
VerDate Sep<11>2014
18:23 Jul 16, 2021
Jkt 253001
38103
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT:
Christine Le, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 75, Rm. 4714, Silver Spring,
MD 20993–0002, 301–796–2398 and/or
PSG-QUESTIONS@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on, among other things, the design of BE
studies to support ANDAs for cilastatin
sodium; imipenem; relebactam for
injection. It does not establish any rights
for any person and is not binding on
FDA or the public. You can use an
alternative approach if it satisfies the
requirements of the applicable statutes
and regulations.
I. Background
In the Federal Register of June 11,
2010 (75 FR 33311), FDA announced the
availability of a guidance for industry
entitled ‘‘Bioequivalence
Recommendations for Specific
Products,’’ which explained the process
that would be used to make productspecific guidances available to the
public on FDA’s website at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs.
As described in that guidance, FDA
adopted this process to develop and
disseminate product-specific guidances
and to provide a meaningful
opportunity for the public to consider
and comment on the guidances. This
notice announces the availability of a
draft guidance on a generic Cilastatin
Sodium; Imipenem; Relebactam for
injection.
FDA initially approved new drug
application 212819 RECARBRIO
(cilastatin sodium; imipenem;
relebactam for injection) in July 2019.
We are now issuing a draft guidance for
industry on generic cilastatin sodium;
imipenem; relebactam for injection
(‘‘Draft Guidance on Cilastatin Sodium;
Imipenem; Relebactam’’).
This draft guidance is being issued
consistent with FDA’s good guidance
[FR Doc. 2021–15170 Filed 7–16–21; 8:45 am]
PO 00000
Frm 00117
Fmt 4703
Sfmt 4703
II. Paperwork Reduction Act of 1995
FDA tentatively concludes that this
draft guidance contains no collection of
information. Therefore, clearance by the
Office of Management and Budget under
the Paperwork Reduction Act of 1995 is
not required.
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, or https://
www.regulations.gov.
Dated: July 12, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
National Vaccine Injury Compensation
Program; List of Petitions Received
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
HRSA is publishing this
notice of petitions received under the
National Vaccine Injury Compensation
Program (the Program), as required by
the Public Health Service (PHS) Act, as
amended. While the Secretary of HHS is
named as the respondent in all
proceedings brought by the filing of
petitions for compensation under the
Program, the United States Court of
Federal Claims is charged by statute
with responsibility for considering and
acting upon the petitions.
FOR FURTHER INFORMATION CONTACT: For
information about requirements for
filing petitions, and the Program in
general, contact Lisa L. Reyes, Clerk of
SUMMARY:
E:\FR\FM\19JYN1.SGM
19JYN1
38104
Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices
Court, United States Court of Federal
Claims, 717 Madison Place NW,
Washington, DC 20005, (202) 357–6400.
For information on HRSA’s role in the
Program, contact the Director, National
Vaccine Injury Compensation Program,
5600 Fishers Lane, Room 08N146B,
Rockville, Maryland 20857; (301) 443–
6593, or visit our website at: https://
www.hrsa.gov/vaccinecompensation/
index.html.
The
Program provides a system of no-fault
compensation for certain individuals
who have been injured by specified
childhood vaccines. Subtitle 2 of Title
XXI of the PHS Act, 42 U.S.C. 300aa–
10 et seq., provides that those seeking
compensation are to file a petition with
the United States Court of Federal
Claims and to serve a copy of the
petition to the Secretary of HHS, who is
named as the respondent in each
proceeding. The Secretary has delegated
this responsibility under the Program to
HRSA. The Court is directed by statute
to appoint special masters who take
evidence, conduct hearings as
appropriate, and make initial decisions
as to eligibility for, and amount of,
compensation.
A petition may be filed with respect
to injuries, disabilities, illnesses,
conditions, and deaths resulting from
vaccines described in the Vaccine Injury
Table (the Table) set forth at 42 CFR
100.3. This Table lists for each covered
childhood vaccine the conditions that
may lead to compensation and, for each
condition, the time period for
occurrence of the first symptom or
manifestation of onset or of significant
aggravation after vaccine
administration. Compensation may also
be awarded for conditions not listed in
the Table and for conditions that are
manifested outside the time periods
specified in the Table, but only if the
petitioner shows that the condition was
caused by one of the listed vaccines.
Section 2112(b)(2) of the PHS Act, 42
U.S.C. 300aa–12(b)(2), requires that
‘‘[w]ithin 30 days after the Secretary
receives service of any petition filed
under section 2111 the Secretary shall
publish notice of such petition in the
Federal Register.’’ Set forth below is a
list of petitions received by HRSA on
June 1, 2021, through June 30, 2021.
This list provides the name of
petitioner, city and state of vaccination
(if unknown then city and state of
person or attorney filing claim), and
case number. In cases where the Court
has redacted the name of a petitioner
and/or the case number, the list reflects
such redaction.
lotter on DSK11XQN23PROD with NOTICES1
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
18:23 Jul 16, 2021
Jkt 253001
Section 2112(b)(2) also provides that
the special master ‘‘shall afford all
interested persons an opportunity to
submit relevant, written information’’
relating to the following:
1. The existence of evidence ‘‘that
there is not a preponderance of the
evidence that the illness, disability,
injury, condition, or death described in
the petition is due to factors unrelated
to the administration of the vaccine
described in the petition,’’ and
2. Any allegation in a petition that the
petitioner either:
a. ‘‘[S]ustained, or had significantly
aggravated, any illness, disability,
injury, or condition not set forth in the
Vaccine Injury Table but which was
caused by’’ one of the vaccines referred
to in the Table, or
b. ‘‘[S]ustained, or had significantly
aggravated, any illness, disability,
injury, or condition set forth in the
Vaccine Injury Table the first symptom
or manifestation of the onset or
significant aggravation of which did not
occur within the time period set forth in
the Table but which was caused by a
vaccine’’ referred to in the Table.
In accordance with Section
2112(b)(2), all interested persons may
submit written information relevant to
the issues described above in the case of
the petitions listed below. Any person
choosing to do so should file an original
and three (3) copies of the information
with the Clerk of the United States
Court of Federal Claims at the address
listed above (under the heading FOR
FURTHER INFORMATION CONTACT), with a
copy to HRSA addressed to Director,
Division of Injury Compensation
Programs, Healthcare Systems Bureau,
5600 Fishers Lane, 08N146B, Rockville,
Maryland 20857. The Court’s caption
(Petitioner’s Name v. Secretary of HHS)
and the docket number assigned to the
petition should be used as the caption
for the written submission. Chapter 35
of title 44, United States Code, related
to paperwork reduction, does not apply
to information required for purposes of
carrying out the Program.
Diana Espinosa,
Acting Administrator.
List of Petitions Filed
1. Kelly Hannon, Washington, District of
Columbia, Court of Federal Claims No:
21–1304V
2. Margaret Hoyt, Washington, District of
Columbia, Court of Federal Claims No:
21–1305V
3. Sarah Lopez, Washington, District of
Columbia, Court of Federal Claims No:
21–1306V
4. Lydia M. Goode, Greensboro, North
Carolina, Court of Federal Claims No:
21–1307V
PO 00000
Frm 00118
Fmt 4703
Sfmt 4703
5. Jonathan Jarog, Chicago, Illinois, Court of
Federal Claims No: 21–1308V
6. Chad Adaway, Birmingham, Alabama,
Court of Federal Claims No: 21–1311V
7. John Buen, Boston, Massachusetts, Court
of Federal Claims No: 21–1314V
8. Robert Ben, Colorado Springs, Colorado,
Court of Federal Claims No: 21–1315V
9. David Plaut, Fort Collins, Colorado, Court
of Federal Claims No: 21–1316V
10. Ciara Johnson, Durango, Colorado, Court
of Federal Claims No: 21–1317V
11. Lindsay Walker on behalf of R.W.,
Aurora, Colorado, Court of Federal
Claims No: 21–1318V
12. Dana Hilden, Phoenix, Arizona, Court of
Federal Claims No: 21–1321V
13. Debbie L. Tice, Jackson, Mississippi,
Court of Federal Claims No: 21–1322V
14. Rhonda Boyd, Huntsville, Alabama, Court
of Federal Claims No: 21–1323V
15. Janice Walker, Ventura, California, Court
of Federal Claims No: 21–1325V
16. Mary Patricia Turner, Washington,
District of Columbia, Court of Federal
Claims No: 21–1327V
17. Kara Mahuron, Washington, District of
Columbia, Court of Federal Claims No:
21–1328V
18. Estate of James Leroy Doebler, Deceased,
Pascagoula, Mississippi, Court of Federal
Claims No: 21–1331V
19. Marlena Lloyd and Jeffrey Lloyd on
behalf of C.L., Boston, Massachusetts,
Court of Federal Claims No: 21–1332V
20. Keith Montague, Boston, Massachusetts,
Court of Federal Claims No: 21–1333V
21. Daniel Murphy, Philadelphia,
Pennsylvania, Court of Federal Claims
No: 21–1334V
22. Jennifer Huch and Lucas Huch on behalf
of L.L.L.H., Bedford, Texas, Court of
Federal Claims No: 21–1335V
23. Michelle Gill on behalf of A.G., Phoenix,
Arizona, Court of Federal Claims No: 21–
1336V
24. Thomas Burbank, Plainville, Connecticut,
Court of Federal Claims No: 21–1337V
25. Clifton Foley and Kelli Foley on behalf
of N.F., Deceased, Burlington, North
Carolina, Court of Federal Claims No:
21–1338V
26. Juanita Artman, Washington, District of
Columbia, Court of Federal Claims No:
21–1340V
27. Ramon K. Jusino and Ann M. Jusino on
behalf of W.J., Staten Island, New York,
Court of Federal Claims No: 21–1342V
28. Nardia Thompson Harris, Nanuet, New
York, Court of Federal Claims No: 21–
1345V
29. Michael Williamson, Murfreesboro,
Tennessee, Court of Federal Claims No:
21–1346V
30. John Allain, Sulphur, Louisiana, Court of
Federal Claims No: 21–1349V
31. Jennifer Clark, Chattanooga, Tennessee,
Court of Federal Claims No: 21–1350V
32. Robert Silver, Shelby, North Carolina,
Court of Federal Claims No: 21–1351V
33. Kelsey Hamonds, Edgewood, Kentucky,
Court of Federal Claims No: 21–1352V
34. Mindy Schuehrer, Marie, Michigan, Court
of Federal Claims No: 21–1353V
35. Hortencia Torres, Annandale, Virginia,
Court of Federal Claims No: 21–1356V
E:\FR\FM\19JYN1.SGM
19JYN1
38105
Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices
36. Laurel Bennett, Washington, District of
Columbia, Court of Federal Claims No:
21–1357V
37. Marie Tully, Washington, District of
Columbia, Court of Federal Claims No:
21–1358V
38. Donna Fulbright, Washington, District of
Columbia, Court of Federal Claims No:
21–1359V
39. Jovonna Beyer, New York, New York,
Court of Federal Claims No: 21–1362V
40. Richard Munoz, Plant City, Florida, Court
of Federal Claims No: 21–1369V
41. Josephine Feitel, Georgetown, Texas,
Court of Federal Claims No: 21–1370V
42. Austin Reid, Louisville, Kentucky, Court
of Federal Claims No: 21–1374V
43. Elizabeth Fellows, Kansas City, Missouri,
Court of Federal Claims No: 21–1378V
44. Stephen R. Hunt, Athens, Ohio, Court of
Federal Claims No: 21–1379V
45. Raymond Milligan, Jr., Sulphur Springs,
Texas, Court of Federal Claims No: 21–
1382V
46. Tina Paxson, Bloomington, Indiana, Court
of Federal Claims No: 21–1383V
47. Rashawnda L. Benton, Greensboro, North
Carolina, Court of Federal Claims No:
21–1384V
48. Jerome Dacurawat, Alexandria, Virginia,
Court of Federal Claims No: 21–1389V
49. Krystal Kilgore, Morristown, Tennessee,
Court of Federal Claims No: 21–1390V
50. Jeffrey A. Ridenour, Lima, Ohio, Court of
Federal Claims No: 21–1392V
51. Lori Kathleen Ogden Erickson, Milton,
Washington, Court of Federal Claims No:
21–1395V
52. Angela Saporito, Nutley, New Jersey,
Court of Federal Claims No: 21–1398V
53. Shawn Wilson-Blount, White Plains, New
York, Court of Federal Claims No: 21–
1400V
54. Geeta Karra, Philadelphia, Pennsylvania,
Court of Federal Claims No: 21–1402V
55. Jonathan Charter, Manchester,
Connecticut, Court of Federal Claims No:
21–1404V
56. Tammy Walden on behalf of J.F.,
Phoenix, Arizona, Court of Federal
Claims No: 21–1406V
57. Bruce A. Ades, Denver, Colorado, Court
of Federal Claims No: 21–1407V
58. Wendy O’Neil, Englewood, New Jersey,
Court of Federal Claims No: 21–1410V
[FR Doc. 2021–15223 Filed 7–16–21; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier: OMB #0990–0475]
Agency Information Collection
Request; 60-Day Public Comment
Request
Office of the Secretary, Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before September 17,
2021.
SUMMARY:
Submit your comments to
Sherrette.Funn@hhs.gov or by calling
(202) 795–7714.
FOR FURTHER INFORMATION CONTACT:
When submitting comments or
requesting information, please include
the document identifier 0990–0475–60D
and project title for reference, to
Sherrette A. Funn, email:
Sherrette.Funn@hhs.gov, or call (202)
795–7714 the Reports Clearance Officer.
SUPPLEMENTARY INFORMATION: Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: ASPA COVID–
19 Public Education Campaign
Evaluation Surveys.
Type of Collection: Extension.
ADDRESSES:
OMB No.: 0990–0475.
Abstract: The Office of the Assistant
Secretary for Public Affairs (ASPA), U.S.
Department of Health and Human
Services (HHS) is requesting an
extension on a currently approved
collection including two components: 1.
COVID–19 Attitudes and Beliefs Survey
(CABS), and 2. Monthly Outcome
Survey (MOS). Throughout execution of
the campaign, this information will
primarily be used by ASPA to determine
whether the campaign is having the
intended impact on target audiences’
knowledge, attitudes, and beliefs as they
relate to COVID–19, COVID–19
vaccination, and adherence to
preventative behaviors. It will also keep
key stakeholders informed of the
Campaign’s progress. Ultimately, the
data will inform a thorough evaluation
of the efficacy of the campaign and its
impact on vaccine uptake.
COVID–19 Attitudes and Beliefs Survey
(CABS)
The CABS is a longitudinal survey
that will be fielded tri-annually to 4,000
U.S. adults over two years (six waves)
via NORC at the University of Chicago’s
AmeriSpeak Panel. The survey will be
fielded online, and each fielding period
will last between 3 and 6 weeks. Those
that respond to wave 1 of the survey
will be recontacted in each wave,
facilitating a comparison of COVID–19
behavior change over time for a
representative sample and evaluation of
U.S. adults. Panel members selected to
participate in the study will receive one
pre-invitation postcard in the mail, one
email invitation, and three email
reminders to complete the survey in
each wave.
Monthly Outcome Survey (MOS)
The MOS is a cross-sectional survey
that will be fielded monthly to 5,000
U.S. adults over two years (24 waves)
via the Ipsos KnowledgePanel 5K
Omnibus Survey. The survey will be
fielded online, and each fielding period
will last between 7 and 10 days.
ANNUALIZED BURDEN HOUR TABLE
lotter on DSK11XQN23PROD with NOTICES1
CABS
Hours to complete survey ........................................................................................................................................
Participants (per wave) ............................................................................................................................................
Number of waves (per year) ....................................................................................................................................
Total respondents per year .....................................................................................................................................
Total burden hours per year ....................................................................................................................................
VerDate Sep<11>2014
18:23 Jul 16, 2021
Jkt 253001
PO 00000
Frm 00119
Fmt 4703
Sfmt 4703
E:\FR\FM\19JYN1.SGM
19JYN1
0.58
4,000
3
12,000
6,960
MOS
0.17
5,000
12
60,000
10,200
]]>Agencies
[Federal Register Volume 86, Number 135 (Monday, July 19, 2021)]
[Notices]
[Pages 38103-38105]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-15223]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
National Vaccine Injury Compensation Program; List of Petitions
Received
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: HRSA is publishing this notice of petitions received under the
National Vaccine Injury Compensation Program (the Program), as required
by the Public Health Service (PHS) Act, as amended. While the Secretary
of HHS is named as the respondent in all proceedings brought by the
filing of petitions for compensation under the Program, the United
States Court of Federal Claims is charged by statute with
responsibility for considering and acting upon the petitions.
FOR FURTHER INFORMATION CONTACT: For information about requirements for
filing petitions, and the Program in general, contact Lisa L. Reyes,
Clerk of
[[Page 38104]]
Court, United States Court of Federal Claims, 717 Madison Place NW,
Washington, DC 20005, (202) 357-6400. For information on HRSA's role in
the Program, contact the Director, National Vaccine Injury Compensation
Program, 5600 Fishers Lane, Room 08N146B, Rockville, Maryland 20857;
(301) 443-6593, or visit our website at: https://www.hrsa.gov/vaccinecompensation/.
SUPPLEMENTARY INFORMATION: The Program provides a system of no-fault
compensation for certain individuals who have been injured by specified
childhood vaccines. Subtitle 2 of Title XXI of the PHS Act, 42 U.S.C.
300aa-10 et seq., provides that those seeking compensation are to file
a petition with the United States Court of Federal Claims and to serve
a copy of the petition to the Secretary of HHS, who is named as the
respondent in each proceeding. The Secretary has delegated this
responsibility under the Program to HRSA. The Court is directed by
statute to appoint special masters who take evidence, conduct hearings
as appropriate, and make initial decisions as to eligibility for, and
amount of, compensation.
A petition may be filed with respect to injuries, disabilities,
illnesses, conditions, and deaths resulting from vaccines described in
the Vaccine Injury Table (the Table) set forth at 42 CFR 100.3. This
Table lists for each covered childhood vaccine the conditions that may
lead to compensation and, for each condition, the time period for
occurrence of the first symptom or manifestation of onset or of
significant aggravation after vaccine administration. Compensation may
also be awarded for conditions not listed in the Table and for
conditions that are manifested outside the time periods specified in
the Table, but only if the petitioner shows that the condition was
caused by one of the listed vaccines.
Section 2112(b)(2) of the PHS Act, 42 U.S.C. 300aa-12(b)(2),
requires that ``[w]ithin 30 days after the Secretary receives service
of any petition filed under section 2111 the Secretary shall publish
notice of such petition in the Federal Register.'' Set forth below is a
list of petitions received by HRSA on June 1, 2021, through June 30,
2021. This list provides the name of petitioner, city and state of
vaccination (if unknown then city and state of person or attorney
filing claim), and case number. In cases where the Court has redacted
the name of a petitioner and/or the case number, the list reflects such
redaction.
Section 2112(b)(2) also provides that the special master ``shall
afford all interested persons an opportunity to submit relevant,
written information'' relating to the following:
1. The existence of evidence ``that there is not a preponderance of
the evidence that the illness, disability, injury, condition, or death
described in the petition is due to factors unrelated to the
administration of the vaccine described in the petition,'' and
2. Any allegation in a petition that the petitioner either:
a. ``[S]ustained, or had significantly aggravated, any illness,
disability, injury, or condition not set forth in the Vaccine Injury
Table but which was caused by'' one of the vaccines referred to in the
Table, or
b. ``[S]ustained, or had significantly aggravated, any illness,
disability, injury, or condition set forth in the Vaccine Injury Table
the first symptom or manifestation of the onset or significant
aggravation of which did not occur within the time period set forth in
the Table but which was caused by a vaccine'' referred to in the Table.
In accordance with Section 2112(b)(2), all interested persons may
submit written information relevant to the issues described above in
the case of the petitions listed below. Any person choosing to do so
should file an original and three (3) copies of the information with
the Clerk of the United States Court of Federal Claims at the address
listed above (under the heading For Further Information Contact), with
a copy to HRSA addressed to Director, Division of Injury Compensation
Programs, Healthcare Systems Bureau, 5600 Fishers Lane, 08N146B,
Rockville, Maryland 20857. The Court's caption (Petitioner's Name v.
Secretary of HHS) and the docket number assigned to the petition should
be used as the caption for the written submission. Chapter 35 of title
44, United States Code, related to paperwork reduction, does not apply
to information required for purposes of carrying out the Program.
Diana Espinosa,
Acting Administrator.
List of Petitions Filed
1. Kelly Hannon, Washington, District of Columbia, Court of Federal
Claims No: 21-1304V
2. Margaret Hoyt, Washington, District of Columbia, Court of Federal
Claims No: 21-1305V
3. Sarah Lopez, Washington, District of Columbia, Court of Federal
Claims No: 21-1306V
4. Lydia M. Goode, Greensboro, North Carolina, Court of Federal
Claims No: 21-1307V
5. Jonathan Jarog, Chicago, Illinois, Court of Federal Claims No:
21-1308V
6. Chad Adaway, Birmingham, Alabama, Court of Federal Claims No: 21-
1311V
7. John Buen, Boston, Massachusetts, Court of Federal Claims No: 21-
1314V
8. Robert Ben, Colorado Springs, Colorado, Court of Federal Claims
No: 21-1315V
9. David Plaut, Fort Collins, Colorado, Court of Federal Claims No:
21-1316V
10. Ciara Johnson, Durango, Colorado, Court of Federal Claims No:
21-1317V
11. Lindsay Walker on behalf of R.W., Aurora, Colorado, Court of
Federal Claims No: 21-1318V
12. Dana Hilden, Phoenix, Arizona, Court of Federal Claims No: 21-
1321V
13. Debbie L. Tice, Jackson, Mississippi, Court of Federal Claims
No: 21-1322V
14. Rhonda Boyd, Huntsville, Alabama, Court of Federal Claims No:
21-1323V
15. Janice Walker, Ventura, California, Court of Federal Claims No:
21-1325V
16. Mary Patricia Turner, Washington, District of Columbia, Court of
Federal Claims No: 21-1327V
17. Kara Mahuron, Washington, District of Columbia, Court of Federal
Claims No: 21-1328V
18. Estate of James Leroy Doebler, Deceased, Pascagoula,
Mississippi, Court of Federal Claims No: 21-1331V
19. Marlena Lloyd and Jeffrey Lloyd on behalf of C.L., Boston,
Massachusetts, Court of Federal Claims No: 21-1332V
20. Keith Montague, Boston, Massachusetts, Court of Federal Claims
No: 21-1333V
21. Daniel Murphy, Philadelphia, Pennsylvania, Court of Federal
Claims No: 21-1334V
22. Jennifer Huch and Lucas Huch on behalf of L.L.L.H., Bedford,
Texas, Court of Federal Claims No: 21-1335V
23. Michelle Gill on behalf of A.G., Phoenix, Arizona, Court of
Federal Claims No: 21-1336V
24. Thomas Burbank, Plainville, Connecticut, Court of Federal Claims
No: 21-1337V
25. Clifton Foley and Kelli Foley on behalf of N.F., Deceased,
Burlington, North Carolina, Court of Federal Claims No: 21-1338V
26. Juanita Artman, Washington, District of Columbia, Court of
Federal Claims No: 21-1340V
27. Ramon K. Jusino and Ann M. Jusino on behalf of W.J., Staten
Island, New York, Court of Federal Claims No: 21-1342V
28. Nardia Thompson Harris, Nanuet, New York, Court of Federal
Claims No: 21-1345V
29. Michael Williamson, Murfreesboro, Tennessee, Court of Federal
Claims No: 21-1346V
30. John Allain, Sulphur, Louisiana, Court of Federal Claims No: 21-
1349V
31. Jennifer Clark, Chattanooga, Tennessee, Court of Federal Claims
No: 21-1350V
32. Robert Silver, Shelby, North Carolina, Court of Federal Claims
No: 21-1351V
33. Kelsey Hamonds, Edgewood, Kentucky, Court of Federal Claims No:
21-1352V
34. Mindy Schuehrer, Marie, Michigan, Court of Federal Claims No:
21-1353V
35. Hortencia Torres, Annandale, Virginia, Court of Federal Claims
No: 21-1356V
[[Page 38105]]
36. Laurel Bennett, Washington, District of Columbia, Court of
Federal Claims No: 21-1357V
37. Marie Tully, Washington, District of Columbia, Court of Federal
Claims No: 21-1358V
38. Donna Fulbright, Washington, District of Columbia, Court of
Federal Claims No: 21-1359V
39. Jovonna Beyer, New York, New York, Court of Federal Claims No:
21-1362V
40. Richard Munoz, Plant City, Florida, Court of Federal Claims No:
21-1369V
41. Josephine Feitel, Georgetown, Texas, Court of Federal Claims No:
21-1370V
42. Austin Reid, Louisville, Kentucky, Court of Federal Claims No:
21-1374V
43. Elizabeth Fellows, Kansas City, Missouri, Court of Federal
Claims No: 21-1378V
44. Stephen R. Hunt, Athens, Ohio, Court of Federal Claims No: 21-
1379V
45. Raymond Milligan, Jr., Sulphur Springs, Texas, Court of Federal
Claims No: 21-1382V
46. Tina Paxson, Bloomington, Indiana, Court of Federal Claims No:
21-1383V
47. Rashawnda L. Benton, Greensboro, North Carolina, Court of
Federal Claims No: 21-1384V
48. Jerome Dacurawat, Alexandria, Virginia, Court of Federal Claims
No: 21-1389V
49. Krystal Kilgore, Morristown, Tennessee, Court of Federal Claims
No: 21-1390V
50. Jeffrey A. Ridenour, Lima, Ohio, Court of Federal Claims No: 21-
1392V
51. Lori Kathleen Ogden Erickson, Milton, Washington, Court of
Federal Claims No: 21-1395V
52. Angela Saporito, Nutley, New Jersey, Court of Federal Claims No:
21-1398V
53. Shawn Wilson-Blount, White Plains, New York, Court of Federal
Claims No: 21-1400V
54. Geeta Karra, Philadelphia, Pennsylvania, Court of Federal Claims
No: 21-1402V
55. Jonathan Charter, Manchester, Connecticut, Court of Federal
Claims No: 21-1404V
56. Tammy Walden on behalf of J.F., Phoenix, Arizona, Court of
Federal Claims No: 21-1406V
57. Bruce A. Ades, Denver, Colorado, Court of Federal Claims No: 21-
1407V
58. Wendy O'Neil, Englewood, New Jersey, Court of Federal Claims No:
21-1410V
[FR Doc. 2021-15223 Filed 7-16-21; 8:45 am]
BILLING CODE 4165-15-P
